{"product_id":"dolaut-40-mg-g-25-g-gel-con-erogatore","title":"Dolaut 40 mg\/g 25 g gel with dispenser","description":"\u003cp\u003e \n\u003cstrong\u003eDolaut 40 mg\/g 25 g gel with dispenser\u003c\/strong\u003e is an \u003cstrong\u003eanti-inflammatory and pain reliever\u003c\/strong\u003e for topical use, formulated for the \u003cstrong\u003elocal treatment of painful and inflammatory conditions\u003c\/strong\u003e of rheumatic or traumatic nature that affect \u003cstrong\u003ejoints, muscles, tendons and ligaments\u003c\/strong\u003e . Thanks to the presence of \u003cstrong\u003ediclofenac sodium\u003c\/strong\u003e , an active ingredient known for its effectiveness, Dolaut gel acts quickly to relieve \u003cstrong\u003emuscle pain, joint pain, inflammation and trauma\u003c\/strong\u003e such as sprains, bruises and rheumatism.\n\u003c\/p\u003e\n\n\u003cp\u003e \nThe practical \u003cstrong\u003e25 g pack with dispenser\u003c\/strong\u003e allows for precise dosing and hygienic application directly on the affected area, promoting rapid absorption without greasing the skin. Its \u003cstrong\u003eskin gel formulation\u003c\/strong\u003e allows for targeted penetration of the active ingredient, providing immediate relief from \u003cstrong\u003erheumatic and traumatic pain\u003c\/strong\u003e and reducing localized inflammation.\n\u003c\/p\u003e\n\n\u003cp\u003e\n Dolaut gel is indicated for those suffering from \u003cstrong\u003erheumatism, joint trauma, tendonitis, muscle pain and inflammation of the ligaments\u003c\/strong\u003e . Regular use helps restore mobility and improve the quality of life in cases of \u003cstrong\u003eacute or chronic pain\u003c\/strong\u003e related to musculoskeletal pathologies. The presence of \u003cstrong\u003epropylene glycol\u003c\/strong\u003e and other selected excipients guarantees a light texture and a sensation of freshness thanks to the mint essence.\n\u003c\/p\u003e\n\n\u003cp\u003e \nChoose \u003cstrong\u003eDolaut 40 mg\/g gel with dispenser\u003c\/strong\u003e for an \u003cstrong\u003eeffective, targeted and practical treatment\u003c\/strong\u003e against \u003cstrong\u003einflammation and muscle-joint pain\u003c\/strong\u003e , ideal for daily use in case of \u003cstrong\u003etrauma, rheumatism and localized pain\u003c\/strong\u003e .\n\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003e ACTIVE INGREDIENTS\u003c\/h2\u003e\n\u003ch3\u003e Active ingredients contained in Dolaut 40 mg\/g 25 g gel with dispenser - What is the active ingredient of Dolaut 40 mg\/g 25 g gel with dispenser?\u003c\/h3\u003e Each 100 g of gel contains: Active ingredient: Diclofenac sodium 4 g Excipient with known effect: propylene glycol For the complete list of excipients, see section 6.1.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e EXCIPIENTS\u003c\/h2\u003e\n\u003ch3\u003e Composition of Dolaut 40 mg\/g 25 g gel with dispenser - What does Dolaut 40 mg\/g 25 g gel with dispenser contain?\u003c\/h3\u003e Propylene glycol, Isopropyl alcohol, Ethyl alcohol, Soy lecithin, Sodium phosphate dihydrate, Disodium phosphate dodecahydrate, Disodium edetate, Ascorbyl palmitate, Peppermint essence, Purified water.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DIRECTIONS\u003c\/h2\u003e  \u003ch3\u003eTherapeutic indications Dolaut 40 mg\/g 25 g gel with dispenser - Why is Dolaut 40 mg\/g 25 g gel with dispenser used? What is it used for?\u003c\/h3\u003e Local treatment of painful and inflammatory conditions of rheumatic or traumatic nature of the joints, muscles, tendons and ligaments.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e CONTRAINDICATIONS AND SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Contraindications Dolaut 40 mg\/g 25 g gel with dispenser - When should Dolaut 40 mg\/g 25 g gel with dispenser not be used?\u003c\/h3\u003e Hypersensitivity to the active substance or to any of the excipients listed in section 6.1. Children and adolescents: Use in children and adolescents under 14 years of age is contraindicated. Patients who have experienced attacks of asthma, urticaria or acute rhinitis after taking acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs (NSAIDs). Third trimester of pregnancy.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e DOSAGE\u003c\/h2\u003e\n\u003ch3\u003e Quantity and method of taking Dolaut 40 mg\/g 25 g gel with dispenser - How to take Dolaut 40 mg\/g 25 g gel with dispenser? \u003c\/h3\u003e\n\u003cb\u003eAdults over 18 years:\u003c\/b\u003e Apply DOLAUT 3 or 4 times a day to the area to be treated, rubbing lightly. The amount to be applied depends on the size of the affected area. For example, 3-5 sprays of DOLAUT are sufficient to treat an area of ​​400-800 cm². After application, wash your hands, otherwise they will also be treated with the gel. Caution: use only for short periods of treatment. \u003cb\u003eAdolescents from 14 to 18 years:\u003c\/b\u003e Apply DOLAUT 3 or 4 times a day to the area to be treated, rubbing lightly. The amount to be applied depends on the size of the affected area. For example, 3-5 sprays of DOLAUT are sufficient to treat an area of ​​400-800 cm². After application, wash your hands, otherwise they will also be treated with the gel. If this product is needed for more than 7 days to relieve pain or if symptoms worsen, consult your doctor. \u003cb\u003eChildren under 14 years:\u003c\/b\u003e There are insufficient data on efficacy and safety in children and adolescents under 14 years of age (see also section 4.3 Contraindications). Therefore, the use of DOLAUT is contraindicated in children under 14 years of age. \u003cb\u003eElderly:\u003c\/b\u003e The usual adult dosage may be used.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eCONSERVATION\u003c\/h2\u003e\n\u003ch3\u003e Storage Dolaut 40 mg\/g 25 g gel with dispenser - How to store Dolaut 40 mg\/g 25 g gel with dispenser?\u003c\/h3\u003e Keep away from heat sources and open flames\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e WARNINGS\u003c\/h2\u003e\n\u003ch3\u003e Warnings Dolaut 40 mg\/g 25 g gel with dispenser - About Dolaut 40 mg\/g 25 g gel with dispenser it is important to know that: \u003c\/h3\u003eThe possibility of systemic adverse events with the application of topical diclofenac cannot be excluded if the preparation is used on large areas of skin and for a prolonged period (see the summary of product characteristics of the systemic forms of diclofenac). Therefore, particularly in patients with previous gastrointestinal diseases, the appearance of systemic side effects such as nausea, dyspepsia, heartburn, excitement, taste disturbance, conjunctivitis cannot be excluded for DOLAUT. Topical Diclofenac should only be applied to intact, non-diseased skin and not to skin wounds or open lesions. It should not be allowed to come into contact with the eyes or mucous membranes and should not be ingested. Discontinue treatment if a skin rash develops after application of the product. DOLAUT contains propylene glycol which may cause mild localized skin irritation in some people. Topical diclofenac may be used with non-occlusive dressings, but should not be used with an airtight occlusive dressing. External use. KEEP OUT OF REACH OF CHILDREN.\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eINTERACTIONS\u003c\/h2\u003e\n\u003ch3\u003e Interactions Dolaut 40 mg\/g 25 g gel with dispenser - Which medicines or foods can modify the effect of Dolaut 40 mg\/g 25 g gel with dispenser?\u003c\/h3\u003e Since systemic absorption of diclofenac following topical application is very low, such interactions are very unlikely.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e SIDE EFFECTS\u003c\/h2\u003e\n\u003ch3\u003e Like all medicines, Dolaut 40 mg\/g 25 g gel with dispenser can cause side effects - What are the side effects of Dolaut 40 mg\/g 25 g gel with dispenser?\u003c\/h3\u003e Adverse reactions (Table 1) are listed by frequency, the most frequent first, using the following convention: very common (≥ 1\/10); common (≥ 1\/100, \u0026lt; 1\/10); uncommon (≥ 1\/1,000, \u0026lt; 1\/100); rare (≥ 1\/10,000, \u0026lt; 1\/1,000); very rare (\u0026lt; 1\/10,000); Not known: frequency cannot be estimated from the available data. \u003cb\u003eTable 1\u003c\/b\u003e\u003ctable border=\"1\" cellspacing=\"0\" cellpadding=\"3\"\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eImmune system disorders\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\u003ctd\u003e Hypersensitivity (including urticaria), angioneurotic edema.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e  \u003ctd colspan=\"2\"\u003e\u003cb\u003eInfections and infestations\u003c\/b\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\u003ctd\u003e Rush with pustules\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eRespiratory, thoracic and mediastinal pathologies\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\u003ctd\u003e Asthma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\u003ctd colspan=\"2\"\u003e \u003cb\u003eSkin and subcutaneous tissue disorders\u003c\/b\u003e\n\u003c\/td\u003e\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Common\u003c\/td\u003e\n\u003ctd\u003e Rash, eczema, erythema, dermatitis (including contact dermatitis), pruritus.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Rare\u003c\/td\u003e\n\u003ctd\u003e Bullous dermatitis.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Very rare\u003c\/td\u003e\n\u003ctd\u003e Photosensitivity reaction\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e Not known\u003c\/td\u003e\n\u003ctd\u003e Burning sensation at application site, dry skin\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e \u003cb\u003eReporting of suspected adverse reactions\u003c\/b\u003e Reporting suspected adverse reactions that occur after authorisation of the medicinal product is important. It allows continued monitoring of the benefit\/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at https:\/\/www.aifa.gov.it\/content\/segnalazioni-reazioni-avverse.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e OVERDOSE\u003c\/h2\u003e  \u003ch3\u003eOverdose Dolaut 40 mg\/g 25 g gel with dispenser - What are the risks of Dolaut 40 mg\/g 25 g gel with dispenser in case of overdose?\u003c\/h3\u003e The low systemic absorption of topical diclofenac makes overdose very unlikely. However, undesirable effects similar to those observed after an overdose of diclofenac tablets may be expected if topical diclofenac is inadvertently ingested (1 bottle of 25 g contains the equivalent of 1000 mg diclofenac sodium). In the event of accidental ingestion resulting in significant systemic undesirable effects, general therapeutic measures normally adopted to treat poisoning with nonsteroidal anti-inflammatory drugs should be undertaken. Gastric decontamination and the use of activated charcoal should be considered, especially within a short time after ingestion.\u003cbr\u003e\n\u003cbr\u003e\u003ch2\u003e PREGNANCY AND BREASTFEEDING\u003c\/h2\u003e  \u003ch3\u003eIf you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking Dolaut 40 mg\/g 25 g gel with dispenser. \u003c\/h3\u003e\n\u003cb\u003ePregnancy\u003c\/b\u003e The systemic concentration of diclofenac, compared to oral formulations, is lower after topical administration. Based on experience with treatment with systemically administered NSAIDs, the following is recommended. Inhibition of prostaglandin synthesis may adversely affect the pregnancy and\/or the embryo\/fetal development. Results of epidemiological studies suggest an increased risk of miscarriage and of cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy. The absolute risk of cardiac malformations increased from less than 1%, up to approximately 1.5%. The risk was believed to increase with dose and duration of therapy. In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality. In addition, an increased incidence of various malformations, including cardiovascular, has been reported in animals given prostaglandin synthesis inhibitors during the organogenetic period. During the first and second trimester of pregnancy, diclofenac should not be given unless clearly necessary. If diclofenac is used by a woman attempting to conceive, or during the first and second trimester of pregnancy, the dose should be kept as low and duration of treatment as short as possible. During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: - cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); - renal dysfunction, which may progress to renal failure with oligo-hydroamniosis; the mother and neonate, at the end of pregnancy, to: - possible prolongation of bleeding time, and an anti-aggregating effect which may occur even at very low doses; - inhibition of uterine contractions resulting in delayed or prolonged labor. Consequently, diclofenac is contraindicated during the third trimester of pregnancy. \u003cb\u003eBreastfeeding\u003c\/b\u003e Like other NSAIDs, diclofenac passes into breast milk in small amounts. However, at therapeutic doses of DOLAUT no effects on the infant are expected. Due to the lack of controlled studies in breastfeeding women, the product should be used during breastfeeding only under the advice of a healthcare professional. In this circumstance, DOLAUT should not be applied to the breasts of nursing mothers, nor elsewhere on large areas of skin or for a prolonged period of time (see section 4.4).\u003cbr\u003e\n\u003cbr\u003e \u003ch2\u003eDRIVING AND USE OF MACHINERY\u003c\/h2\u003e\n\u003ch3\u003e Taking Dolaut 40 mg\/g 25 g gel with dispenser before driving or using machines - Does Dolaut 40 mg\/g 25 g gel with dispenser affect driving or using machines?\u003c\/h3\u003e The cutaneous application of topical diclofenac does not alter the ability to drive vehicles or use machinery.","brand":"NEOPHARMED GENTILI SpA","offers":[{"title":"Default Title","offer_id":51730203115847,"sku":"033913017","price":16.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0564\/4989\/2467\/files\/neopharmed-gentili-spa-dolaut-40-mg-g-25-g-gel-con-erogatore-farmacia-dottor-tili-1213791433.jpg?v=1767138450","url":"https:\/\/www.dottortili.com\/en\/products\/dolaut-40-mg-g-25-g-gel-with-dispenser","provider":"Farmacia Dottor Tili","version":"1.0","type":"link"}